AZN AstraZeneca PLC

Mentions (63)

• Newscnbc.com·18h ago·Negative

  AstraZeneca CEO says Summit drug could drive next generation of cancer combinations after $2 billion investment AstraZeneca CEO Pascal Soriot told CNBC that Summit Therapeutics' lead drug could help power next-generation cancer combinations that could be the "future of cancer care." Soriot spoke exclusively with CNBC from the site of AstraZeneca's new more than $1 billion research and development facility in Kendall Square in Cambridge, Massachusetts.

  View source ↗
• Newsreuters.com·4d ago·Negative

  AstraZeneca, Daiichi Sankyo partner with Summit to test cancer drug combination AstraZeneca and Daiichi Sankyo have entered into ​a clinical collaboration with ‌Summit Therapeutics to test their cancer drug, Datroway, in ​combination with Summit's ​ivonescimab across multiple tumour types, ⁠including lung and breast ​cancers.

  View source ↗
• Newsbusinesswire.com·4d ago·Negative

  …IRE)--Summit Therapeutics Inc. (Nasdaq: SMMT) today announced a clinical trial collaboration agreement with Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/NYSE: AZN) to evaluate ivonescimab, a novel, potential first-in-class investigational PD-1 / VEGF bispecific antibody, in combination with Datroway® (datopotamab deruxtecan), a TROP2-directed antibody drug conjugate (ADC), across multiple solid tumor settings, intending to include breast and lung cancer. The companies i.

  View source ↗
• Newsbusinesswire.com·4d ago·Neutral

  …s to Evaluate Datroway® in Combination with Ivonescimab Across Multiple Tumor Types TOKYO--(BUSINESS WIRE)--Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/NYSE: AZN) have entered into a clinical trial collaboration agreement with Summit Therapeutics Inc. (Nasdaq: SMMT) to evaluate Datroway® (datopotamab deruxtecan) in combination with ivonescimab across multiple tumor types including lung and breast cancers. The companies intend to begin with a phase 3 trial in first-line triple negative br…

  View source ↗
• News247wallst.com·5d ago·Neutral

  AstraZeneca's $2 Billion Vote of Confidence Leaves Summit Therapeutics Trading Well Below Street Targets AstraZeneca just locked in a price to own 12% of Summit Therapeutics that the open market refuses to match, and two clinical deadlines in 2026 will determine whether Wall Street or the pharma giant read ivonescimab correctly.

  View source ↗
• Newszacks.com·6d ago·Neutral

  Astrazeneca (AZN) Registers a Bigger Fall Than the Market: Important Facts to Note Astrazeneca (AZN) closed at $164.21 in the latest trading session, marking a -1.17% move from the prior day.

  View source ↗
• Newszacks.com·6d ago·Neutral

  Summit Shares Jump on $2B Strategic Investment From AstraZeneca SMMT shares jump as AstraZeneca commits $2 billion to accelerate ivonescimab development and expand clinical collaboration.

  View source ↗
• Newsproactiveinvestors.com·7d ago·Negative

  AstraZeneca's $2 billion Summit stake wins backing from UBS and Jefferies AstraZeneca PLC (LSE:AZN, NASDAQ:AZN), the FTSE 100 pharmaceutical company, has won positive responses from UBS and Jefferies after investing $2 billion in Summit Therapeutics and agreeing a cancer drug collaboration.  UBS said the investment gives AstraZeneca exposure to the programmed death-1 and vascular endothelial growth factor (PD-1/VEGF) class, which combines immune-system activation with inhibition of tumour blood …

  View source ↗
• Newsinvezz.com·7d ago·Neutral

  Summit Therapeutics jumps 20% after AstraZeneca's $2 billion bet: what it signals Summit Therapeutics shares surged more than 20% in pre-market trading on Tuesday after AstraZeneca agreed to invest $2 billion in the company and collaborate on a series of clinical studies involving their cancer treatments. The deal, announced late Monday, sent UK-listed shares of AstraZeneca 1.9% higher to a two-month high.

  View source ↗
• Newsreuters.com·7d ago·Negative

  Summit soars after $2 billion investment from AstraZeneca for cancer therapies Summit Therapeutics' shares rose 23% in premarket trading on Tuesday after the drugmaker said AstraZeneca would invest $2 billion in the company ​to test cancer treatments together.

  View source ↗
• Newsproactiveinvestors.com·7d ago·Negative

  AstraZeneca invests $2 billion in Summit Therapeutics in cancer drug deal AstraZeneca PLC (LSE:AZN, NASDAQ:AZN), the FTSE 100 pharmaceutical company, will invest $2 billion in Summit Therapeutics Inc. as part of a wider cancer drug collaboration.

  View source ↗
• Newstheguardian.com·7d ago·Negative

  Anthropic warns of ‘existential risks to humanity' from AI; AstraZeneca makes $2bn cancer drug tie-up – business live Rolling coverage of the latest economic and financial news

  View source ↗
• Newsreuters.com·7d ago·Negative

  AstraZeneca files US FDA application for HUTCHMED lung cancer drug combination HUTCHMED (China) said on ​Tuesday Anglo-Swedish ‌drugmaker AstraZeneca had filed ​an ​application with the US ⁠Food ​and Drug ​Administration for approval of the ​ORPATHYS-TAGRISSO combination ​in patients with ‌advanced ⁠lung cancer.

  View source ↗
• Newswsj.com·7d ago·Negative

  AstraZeneca to Invest $2 Billion in Summit Therapeutics, Collaborate on Cancer Drugs Summit shares surged in after-hours trading following the news of AstraZeneca's investment, as the two companies plan to ramp up their collaboration on developing cancer treatments.

  View source ↗
• Newsreuters.com·7d ago·Negative

  AstraZeneca to invest $2 billion in Summit Therapeutics for cancer drug tie-up Summit Therapeutics said on Monday that British drugmaker AstraZeneca would invest $2 billion in ​the company and collaborate on a ‌series of studies testing their cancer treatments together.

  View source ↗
• Newsbusinesswire.com·7d ago·Neutral

  …ing its goal of making a significant difference in the lives of patients with cancer. Specifically, Summit has established agreements with AstraZeneca (LSE/STO/NYSE: AZN) for a strategic equity investment in Summit and a clinical collaboration focused on ivonescimab and sonesitatug vedotin (sone-ve). Moreover, Summit and AstraZeneca intend to evaluat.

  View source ↗
• Newsbusinesswire.com·7d ago·Neutral

  Eccogene Receives $50 Million Milestone Payment from AstraZeneca Following Initiation of Global Phase 3 Program for Elecoglipron (AZD5004/ECC5004) BOSTON & SHANGHAI--(BUSINESS WIRE)--Eccogene Receives $50 Million Milestone Payment from AstraZeneca Following Initiation of Global Phase 3 Program for Elecoglipron (AZD5004/ECC5004).

  View source ↗
• Newszacks.com·7d ago·Negative

  Is AstraZeneca's Oncology Portfolio Positioned for Continued Growth? AZN's oncology sales rise 15% in H1 2026 as newer drugs, label expansions and a deep pipeline support continued franchise growth.

  View source ↗
• Newsseekingalpha.com·11d ago·Positive

  …veraging mid-single-digit revenue growth into robust EPS gains, driven by oncology and pipeline execution. Recent EU approval of Trixeo Aerosphere for asthma expands AZN's addressable market, reinforcing its Respiratory & Immunology franchise with durable, long-cycle growth potential. AZN's pipeline momentum—six positive Phase III readouts and 30 approvals—underpins its long-term growth narrative despite isolated late-stage failures.

  View source ↗
• Newsbusinesswire.com·11d ago·Negative

  Perioperative IMFINZI® (durvalumab) plus neoadjuvant enfortumab vedotin granted Priority Review in the US for patients with muscle-invasive bladder cancer WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca's supplemental Biologics License Application (sBLA) for IMFINZI® (durvalumab) in combination with enfortumab vedotin (EV) has been accepted and granted Priority Review in the US for the treatment of patients with muscle-invasive bladder cancer (MIBC) who are ineligible for or have declined cisplat

  View source ↗
• Newszacks.com·12d ago·Negative

  Ionis Delivers Positive Late-Stage Results for Two Partnered Drugs IONS posts positive phase III results for two partnered drugs, with ulefnersen meeting its ALS endpoint and sefaxersen cutting proteinuria.

  View source ↗
• Newszacks.com·12d ago·Neutral

  AstraZeneca's Trixeo Secures Approval for Asthma in the EU AZN's Trixeo wins EU approval for asthma, adding an indication backed by phase III data showing improved lung function.

  View source ↗
• Newszacks.com·14d ago·Neutral

  Astrazeneca (AZN) Ascends But Remains Behind Market: Some Facts to Note In the latest trading session, Astrazeneca (AZN) closed at $168.1, marking a +1.22% move from the previous day.

  View source ↗
• Newszacks.com·14d ago·Neutral

  AZN's Klygefa Gets CHMP Nod for Generalised Myasthenia Gravis in EU AstraZeneca's Klygefa wins a positive EU recommendation for AChR-positive gMG, backed by phase III data and a convenient once-weekly treatment option.

  View source ↗
• Newszacks.com·14d ago·Neutral

  AZN vs. MRK: Comparing Keytruda, Pipelines and Growth Strategies AZN and MRK bring distinct oncology strengths, growth plans, pipeline opportunities and patent-related challenges to the table.

  View source ↗
• Newszacks.com·17d ago·Negative

  FDA Grants Priority Review to AZN's Filing for Rare Bone Disease Drug AstraZeneca wins FDA priority review for efzimfotase alfa, potentially expanding its HPP treatment opportunity with less frequent dosing.

  View source ↗
• Newsreuters.com·19d ago·Negative

  AstraZeneca-Daiichi breast cancer drug cleared for NHS use in England AstraZeneca and Daiichi Sankyo said on Thursday their breast cancer treatment Enhertu has been approved for use in England's ​state-run healthcare system, expanding access to a drug that ‌has been available in Scotland since 2023.

  View source ↗
• Newszacks.com·19d ago·Positive

  Is It Worth Investing in Astrazeneca (AZN) Based on Wall Street's Bullish Views? The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.

  View source ↗
• Newszacks.com·21d ago·Neutral

  Why the Market Dipped But Astrazeneca (AZN) Gained Today In the latest trading session, Astrazeneca (AZN) closed at $163.78, marking a +2.25% move from the previous day.

  View source ↗
• Newszacks.com·21d ago·Neutral

  AZN's Etcamah Fails Late-Stage Study for First-line Breast Cancer AstraZeneca's Etcamah fails to improve PFS significantly in a phase III first-line breast cancer study, while its approved use remains unaffected.

  View source ↗
• Newswsj.com·22d ago·Negative

  AstraZeneca Breast-Cancer Drug Misses Goal in Late-Stage Trial The Etcamah results came a week after the U.S. granted approval for the drug for advanced breast cancer upon the detection of a specific mutation.

  View source ↗
• Newsmarketbeat.com·23d ago·Negative

  AstraZeneca COPD Drug Cuts Exacerbations as FDA Priority Review Nears Astrazeneca NYSE: AZN presented Phase III data for tozorakimab in chronic obstructive pulmonary disease, or COPD, at the 2026 European Respiratory Society Congress in Barcelona, reporting statistically significant reductions in moderate-to-severe exacerbations across two trials and across a broad range of patient subgroups.

  View source ↗
• Newsseekingalpha.com·24d ago·Negative

  AstraZeneca: The $5 Billion Pipeline Hole Did Not Stay Open Long Wainua's July failure erased more than $30 billion of AstraZeneca's market value and raised questions about a pipeline investors had learned to trust. The full tozorakimab results are more interesting than the earlier headline. COPD attacks fell by 29% to 34% in two large Phase III trials. A 23% reduction among patients with low eosinophil counts could open a part of the COPD market that existing biologics do not serve well.

  View source ↗
• Newsinvestors.com·24d ago·Positive

  AstraZeneca Stock Trips On Unexpected Failure In Breast Cancer AstraZeneca stock toppled in late trades Friday after the company's experimental breast cancer treatment failed to pass muster.

  View source ↗
• Newsreuters.com·24d ago·Negative

  Astrazeneca's breast cancer drug fails late-stage trial AstraZeneca ​said on ‌Friday ​its ​breast cancer ⁠drug ​failed to ​meet the ​main ​goal of improving ‌progression-free ⁠survival during ​a ​late-stage ⁠trial.

  View source ↗
• Newsproactiveinvestors.co.uk·26d ago·Negative

  AstraZeneca's $5bn drug promise is no 'buy' signal for Deutsche AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) drew praise from Deutsche Bank for tozorakimab's lung disease data, but the broker paired its positive assessment with a bearish verdict on the shares. The shares traded at 11,634p, broadly flat, while the bank rated the drugmaker 'sell' with a target price of 11,500 pence.

  View source ↗
• Newsproactiveinvestors.co.uk·27d ago·Positive

  AstraZeneca COPD data back Citi's $7b peak sales case AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) drew Citi's backing after tozorakimab trial results, supporting an upside case of at least $7 billion in peak sales, roughly twice consensus. Behind the bullish call, phase III data presented at the European Respiratory Society meeting showed tozorakimab reduced flare-ups in chronic obstructive pulmonary disease (COPD).

  View source ↗
• Newsreuters.com·27d ago·Negative

  AstraZeneca drug reduces lung disease flare-ups in late-stage trials Today we feature data from studies being presented at the ongoing European Respiratory Society Congress in Barcelona.

  View source ↗
• Newsseekingalpha.com·27d ago·Positive

  AstraZeneca PLC (AZN) Presents at European Respiratory Society (ERS) Congress Transcript AstraZeneca PLC (AZN) Presents at European Respiratory Society (ERS) Congress Transcript

  View source ↗
• Newswsj.com·28d ago·Negative

  AstraZeneca Says Lung-Disease Drug Shows Benefits Across Patient Groups AstraZeneca said its new drug for COPD showed benefits across a broad patient population in late-stage clinical trials, boosting a medicine the company expects to generate multibillion-dollar sales.

  View source ↗
• Newsreuters.com·28d ago·Negative

  AstraZeneca's cancer drug combo hits main survival goal in late-stage trial AstraZeneca said ​on Tuesday its ‌cancer drug Imfinzi ​combined ​with Amgen's targeted ⁠immunotherapy ​Imdelltra ​significantly improved overall survival ​in ​first-line extensive-stage ‌small ⁠cell lung cancer in ​a ​late-stage ⁠trial.

  View source ↗
• Newscnbc.com·28d ago·Negative

  AstraZeneca's COPD drug scores two late-stage trial wins as full data boosts blockbuster hopes AstraZeneca released full results from two successful late-stage trials on its experimental drug for chronic obstructive pulmonary disease. The detailed data reinforces hopes that the product could be a breakthrough treatment for COPD and reach AstraZeneca's peak annual sales forecast of more than $5 billion for the drug.

  View source ↗
• Newsproactiveinvestors.co.uk·28d ago·Negative

  Citi backs AstraZeneca sentiment boost after Etcamah wins accelerated FDA approval Citi has flagged AstraZeneca PLC's (LSE:AZN, NASDAQ:AZN) accelerated approval for Etcamah, known chemically as camizestrant, as a meaningful sentiment driver for the shares. The oral selective oestrogen receptor degrader has been cleared by the US Food and Drug Administration in combination with a CDK4/6 inhibitor for hormone receptor positive, HER2 negative metastatic breast cancer.

  View source ↗
• Newszacks.com·29d ago·Neutral

  AstraZeneca Secures FDA Nod for New Breast Cancer Therapy Etcamah AZN's Etcamah wins accelerated FDA approval for certain advanced breast cancer patients, backed by a 56% risk reduction in progression or death.

  View source ↗
• Newsbusinesswire.com·31d ago·Negative

  Guardant Health Announces Landmark FDA Approval of Guardant360® CDx as Companion Diagnostic for AstraZeneca's ETCAMAH™ (camizestrant) in Advanced Breast Cancer PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that the U.S. Food and Drug Administration (FDA) has approved Guardant360® CDx as a companion diagnostic (CDx) to identify patients with hormone receptor (HR)-positive, HER2-negative advanced or metastatic breast c

  View source ↗
• Newszacks.com·33d ago·Negative

  AZN Stock Down 20% in 6 Months: How to Play After Pipeline Setbacks AstraZeneca's pipeline setbacks weigh on the stock, but blockbuster drugs, oncology growth and a strong launch pipeline offer reasons to stay invested.

  View source ↗
• Newszacks.com·33d ago·Positive

  AZN's Tagrisso Plus Orpathys Study in First-Line NSCLC Meets Goal AstraZeneca reports positive SANOVO data, showing Tagrisso plus Orpathys improved PFS in first-line EGFR-mutated NSCLC.

  View source ↗
• Newsreuters.com·35d ago·Negative

  AstraZeneca lung cancer therapy combination shows promise in advanced study AstraZeneca said ​on Tuesday ‌that a Chinese ​late-stage ​trial of a ⁠combination of ​its ​cancer drugs Tagrisso and Orpathys ​significantly ​improved progression-free survival ‌when ⁠given as a first-line ​treatment ​for ⁠a type ​of ​lung ⁠cancer.

  View source ↗
• Newszacks.com·39d ago·Neutral

  AZN/AMGN's Tezspire Hits Primary Goal in Eosinophilic Esophagitis Study AstraZeneca's Tezspire delivers positive CROSSING data in EoE, meeting all primary and secondary endpoints and supporting its expansion potential.

  View source ↗
• Newszacks.com·39d ago·Neutral

  Oncology Stocks to Add to Your Portfolio as Cancer Care Evolves Oncology innovation is driving new treatment options, with Iovance, Merit Medical and Kura advancing cancer-focused therapies and technologies.

  View source ↗
• Newsproactiveinvestors.co.uk·40d ago·Negative

  AstraZeneca drug succeeds in trial for swallowing disorder AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) said its drug Tezspire worked in a late-stage trial of patients with eosinophilic esophagitis, a chronic condition that inflames the gullet and makes swallowing difficult. The drug, developed with the American biotech company Amgen, hit both of its main goals and every important secondary one.

  View source ↗
• Newsreuters.com·40d ago·Negative

  AstraZeneca's asthma drug Tezspire meets all goals in late-stage esophagitis trial AstraZeneca said ​on Thursday ‌its asthma drug, ​Tezspire, ​developed with Amgen , ⁠met ​its main ​and secondary goals in ​a ​late-stage trial for ‌treating ⁠eosinophilic esophagitis, a chronic ​inflammatory ​disorder ⁠of the ​esophagus.

  View source ↗
• Newsproactiveinvestors.co.uk·42d ago·Neutral

  AstraZeneca prices €2.55bn euro bond sale across four tranches AstraZeneca PLC (LSE:AZN, NASDAQ:AZN), the FTSE 100 pharma group, has priced a €2.55 billion bond offering, tapping the euro debt market for general corporate purposes. The notes were issued on Monday by AstraZeneca Finance LLC, a wholly owned US subsidiary, and carry a full and unconditional guarantee from the parent company.

  View source ↗
• Newszacks.com·47d ago·Positive

  BioMarin Inks $490M Deal to Buy Rare Bone Disease Treatment BMRN's $490M Alesta deal adds ALE1, a potential oral HPP therapy, broadening its rare bone disease portfolio and clinical pipeline.

  View source ↗
• Newsseekingalpha.com·48d ago·Negative

  AstraZeneca Vs. Bristol-Myers Squibb: Who's The Better Bargain For Investors? Rumors of an AstraZeneca PLC-Bristol-Myers Squibb Company merger are cooling, yet each company's standalone strength deserves closer scrutiny. Overall, AZN and BMY occupy leading positions in the cancer and immune-mediated inflammatory diseases markets. Each of them has advantages, as well as dark spots in the portfolio of drugs relative to the rival.

  View source ↗
• Newszacks.com·48d ago·Neutral

  AZN Ends NSCLC Study for Bispecific Antibody Over Unlikely Success AstraZeneca halts a phase III NSCLC study for volrustomig after data show that the regimen is unlikely to meet key survival goals, while other lung cancer trials shine.

  View source ↗
• Newsproactiveinvestors.co.uk·49d ago·Positive

  AstraZeneca maintains Citi 'buy' rating despite mixed pipeline updates AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) has retained a 'buy' rating from Citi following a mixed set of pipeline updates, with the broker saying its underlying investment thesis remains unchanged and that the drugmaker continues to offer the strongest growth and pipeline profile in the sector. Citi highlighted positive results from the Phase III SAFFRON trial, where Tagrisso plus Orpathys met the primary endpoint and demonstrate…

  View source ↗
• Newsbenzinga.com·50d ago·Negative

  AstraZeneca Reports Mixed Lung Cancer Trial Outcomes From Three Pivotal Studies AstraZeneca Plc (NYSE:AZN) on Monday reported a mix of clinical trial outcomes for its lung cancer treatments, achieving notable successes in two late-stage trials while discontinuing a third study due to missed primary endpoints.

  View source ↗
• Newsproactiveinvestors.co.uk·50d ago·Neutral

  AstraZeneca lung cancer drug combination extends survival in trial AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) has reported positive results from a late-stage trial of a two-drug combination for a hard-to-treat form of lung cancer, potentially opening the way to approval around the world. The study tested the company's established lung cancer pill Tagrisso alongside a newer drug called Orpathys, developed with the Hong Kong-based biotech HUTCHMED.

  View source ↗
• Newswsj.com·50d ago·Negative

  AstraZeneca Ends Phase Three Lung Cancer Drug Trial After Review The decision was based on the recommendation of the Independent Data Monitoring Committee, which said volrustomig plus chemotherapy was unlikely to reach primary endpoints.

  View source ↗
• Newsreuters.com·50d ago·Neutral

  AstraZeneca to discontinue late-stage lung cancer trial for volrustomig AstraZeneca on Monday said it is discontinuing ​a late stage trial ‌that tested volrustomig plus chemotherapy in patients with metastatic non-small cell ​lung cancer.

  View source ↗
• Newsfool.com·53d ago·Neutral

  Is the Reported $400 Billion AstraZeneca-Bristol Myers Squibb Megamerger a Slam Dunk -- or a Disaster Waiting to Happen? Earlier this month, AstraZeneca and Bristol Myers Squibb became the subject of merger rumors. Investors reacted negatively to the rumors, even if on paper such a deal would create an oncology-focused big pharma powerhouse worth around $400 billion.

  View source ↗
• Newszacks.com·55d ago·Neutral

  Do Options Traders Know Something About AstraZeneca Stock We Don't? Investors need to pay close attention to AZN stock based on the movements in the options market lately.

  View source ↗